BH3 mimetics as a strategy to complement anticancer therapies;Mimetyki BH3 jako terapia wspomagaja̧ca konwencjonalne leki przeciwnowotworowe

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 66, Issue , 2012, Pages 67-77

  Hartman, Mariusz Ł ^a   Czyz, Małgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Anticancer therapy; Apoptosis; Bcl 2 proteins; BH3 mimetics; BH3 only proteins

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BAX PROTEIN (53 86); BAX PROTEIN (53-86); ONCOPROTEIN; PEPTIDE FRAGMENT;

APOPTOSIS; BIOMIMETICS; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; NEOPLASM; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIOMIMETICS; HUMANS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NEOPLASMS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS;

EID: 84867978350     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Adams J. M., Cory S.: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 2007;26:1324-1337
2. Arisan E. D., Kutuk O., Tezil T., Bodur C., Telci D., Basaga H.: Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells. Breast Cancer Res. Treat., 2010;119:271-281
3. Ashimori N., Zeitlin B. D., Zhang Z., Warner K., Turkienicz I. M., Spalding A. C., Teknos T. N., Wang S., Nör J. E.: TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol. Cancer Ther., 2009;8:893-903
4. Balakrishnan K., Burger J. A., Wierda W. G., Gandhi V.: AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood, 2009;113:149-153
5. Baskin-Bey E. S., Gores G. J.: Death by association: BH3 domain-only proteins and liver injury. Am. J. Physiol. Gastrointest. Liver Physiol., 2005;289:G987-G990
6. L. Chem. Biol., 2004;11:389-395
7. Buron N., Porceddu M., Brabant M., Desgué D., Racoeur C., Lassalle M., Péchoux C., Rustin P., Jacotot E., Borgne-Sanchez A.: Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. PLoS One, 2010;5:e9924
8. Certo M., del Gaizo Moore V., Nishino M., Wei G., Korsmeyer S., Armstrong S. A., Letai A.: Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell, 2006;9:351-365
9. Chang J. S., Hsu Y. L., Kuo P. L., Chiang L. C., Lin C. C.: Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line. Clin. Exp. Pharmacol. Physiol., 2004;31:716-722
10. Chen J., Freeman A., Liu J., Dai Q., Lee R. M.: The apoptotic effect of HA14-1, a Bcl-2-interacting small molecular compound, requires Bax translocation and is enhanced by PK11195. Mol. Cancer Ther., 2002;1:961-967
11. Chen S., Dai Y., Harada H., Dent P., Grant S.: Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res., 2007;67:782-791
12. Chipuk J. E., Moldoveanu T., Llambi F., Parsons M. J., Green D. R.: The BCL-2 family reunion. Mol. Cell, 2010;37:299-310
13. Chonghaile T. N., Letai A.: Mimicking the BH3 domain to kill cancer cells. Oncogene, 2008;27(Suppl.1):S149-S157
14. Clinical trials. http://clinicaltrials.gov/ct2/home (29.11.2011)
15. Cragg M. S., Jansen E. S., Cook M., Harris C., Strasser A., Scott C. L.: Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J. Clin. Invest., 2008;118:3651-3659
16. Dean E. J., Cummings J., Roulston A., Berger M., Ranson M., Blackhall F., Dive C.: Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Neoplasia, 2011;13:339-347
17. L. Nat. Cell Biol., 2001;3:173-182
18. Del Gaizo Moore V., Brown J. R., Certo M., Love T. M., Novina C. D., Letai A.: Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest., 2007;117:112-121
19. Del Gaizo Moore V., Letai A.: BH3 profiling - measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett., 2012 (w druku)
20. Deoras D. P., Young-Curtis P., Dalvi R. R., Tippett F. E.: Effect of gossypol on hepatic and serum γ-glutamyltransferase activity in rats. Vet. Res. Commun., 1997;21:317-323
21. Dewson G., Kluck R. M.: Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. J. Cell Sci., 2009;122:2801-2808
22. Elkholi R., Floros K. V., Chipuk J. E.: The role of BH3-only proteins in tumor cell development, signaling and treatment. Genes Cancer, 2011;2:523-537
23. Etxebarria A., Landeta O., Antonsson B., Basañez G.: Regulation of antiapoptotic MCL-1 function by gossypol: mechanistic insights from in vitro reconstituted systems. Biochem. Pharmacol., 2008;76:1563-1576
24. Fricker M., O'Prey J., Tolkovsky A. M., Ryan K. M.: Phosphorylation of Puma modulates its apoptotic function by regulating protein stability. Cell Death Dis., 2010;1:e59
25. Gao P., Bauvy C., Souquère S., Tonelli G., Liu L., Zhu Y., Qiao Z., Bakula D., Proikas-Cezanne T., Pierron G., Codogno P., Chen Q., Mehrpour M.: The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells. J. Biol. Chem., 2010;285:25570-25581
26. Gavathiotis E., Suzuki M., Davis M. L., Pitter K., Bird G. H., Katz S. G., Tu H. C., Kim H., Cheng E. H., Tjandra N., Walensky L. D.: BAX activation is initiated at a novel interaction site. Nature, 2008;455:1076-1081
27. Gilbert N. E., O'Reilly J. E., Chang C. J., Lin Y. C., Brueggemeier R. W.: Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci., 1995;57:61-67
28. Goldsmith K. C., Liu X., Dam V., Morgan B. T., Shabbout M., Cnaan A., Letai A., Korsmeyer S. J., Hogarty M. D.: BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma. Oncogene, 2006;25:4525-4533
29. Goldstein N. B., Johannes W. U., Gadeliya A. V., Green M. R., Fujita M., Norris D. A., Shellman Y. G.: Active N-Ras and B-Raf inhibit anoikis by downregulating Bim expression in melanocytic cells. J. Invest. Dermatol., 2009;129:432-437
30. Ham J., Towers E., Gilley J., Terzano S., Randall R.: BH3-only proteins: key regulators of neuronal apoptosis. Cell Death Differ., 2005;12:1015-1020
31. Hanahan D., Weinberg R. A.: Hallmarks of cancer: the next generation. Cell, 2011;144:646-674
32. Hao J. H., Yu M., Liu F. T., Newland A. C., Jia L.: Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res., 2004;64:3607-3616
33. Harford T. J., Shaltouki A., Weyman C. M.: Increased expression of the pro-apoptotic Bcl2 family member PUMA and apoptosis by the muscle regulatory transcription factor MyoD in response to a variety of stimuli. Apoptosis, 2010;15:71-82
34. Harrison L. R., Micha D., Brandenburg M., Simpson K. L., Morrow C. J., Denneny O., Hodgkinson C., Yunus Z., Dempsey C., Roberts D., Blackhall F., Makin G., Dive C.: Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. J. Clin. Invest., 2011;121:1075-1087
35. Huang L. H., Hu J. Q., Tao W. Q., Li Y. H., Li G. M., Xie P. Y., Liu X. S., Jiang J.: Gossypol inhibits phosphorylation of Bcl-2 in human leukemia HL-60 cells. Eur. J. Pharmacol., 2010;645:9-13
36. Huang S., Sinicrope F. A.: BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res., 2008;68:2944-2951
37. Huang Y. W., Wang L. S., Dowd M. K., Wan P. J., Lin Y. C.: (-)-Gossypol reduces invasiveness in metastatic prostate cancer cells. Anticancer Res., 2009;29:2179-2188
38. Hutchinson R. W., Ing N. H., Burghardt R. C.: Induction of c-fos, and cytochrome c oxidase subunits I and II by gossypol acetic acid in rat liver cells. Cell Biol. Toxicol., 1998;14:391-399
39. Jóna A., Khaskhely N., Buglio D., Shafer J. A., Derenzini E., Bollard C. M., Medeiros L. J., Illés A., Ji Y., Younes A.: The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp. Hematol., 2011;39:1007-1017.e1
40. Junttila M. R., Evan G. I.: p53 - a Jack of all trades but master of none. Nat. Rev. Cancer, 2009;9:821-829
41. Kang M. H., Kang Y. H., Szymanska B., Wilczynska-Kalak U., Sheard M. A., Harned T. M., Lock R. B., Reynolds C. P.: Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood, 2007;110:2057-2066
42. Keuling A. M., Andrew S. E., Tron V. A.: Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA. Pigment Cell Melanoma Res., 2010;23:430-440
43. Kim H., Tu H. C., Ren D., Takeuchi O., Jeffers J. R., Zambetti G. P., Hsieh J. J., Cheng E. H.: Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol. Cell, 2009;36:487-499
44. King M. A.: Antimycin A-induced killing of HL-60 cells: apoptosis initiated from within mitochondria does not necessarily proceed via caspase 9. Cytometry A, 2005;63:69-76
45. Kitada S., Kress C. L., Krajewska M., Jia L., Pellecchia M., Reed J. C.: Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood, 2008;111:3211-3219
46. Konopleva M., Watt J., Contractor R., Tsao T., Harris D., Estrov Z., Bornmann W., Kantarjian H., Viallet J., Samudio I., Andreeff M.: Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (Obatoclax). Cancer Res., 2008;68:3413-3420
47. Kuroda J., Taniwaki M.: Involvement of BH3-only proteins in hematologic malignancies. Crit. Rev. Oncol. Hematol., 2009;71:89-101
48. L recognition by a BH3-mimetic α/β-peptide generated by sequence-based design. Chembiochem, 2011;12:2025-2032
49. Letai A., Bassik M. C., Walensky L. D., Sorcinelli M. D., Weiler S., Korsmeyer S. J.: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2002;2:183-192
50. Li J., Viallet J., Haura E. B.: A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother. Pharmacol., 2008;61:525-534
51. Liu Y., Li Y., Wang H., Yu J., Lin H., Xu D., Wang Y., Liang A., Liang X., Zhang X., Fu M., Qian H., Lin C.: BH3-based fusion artificial peptide induces apoptosis and targets human colon cancer. Mol. Ther., 2009;17:1509-1516
52. Lomonosova E., Chinnadurai G.: BH3-only proteins in apoptosis and beyond: an overview. Oncogene, 2008;27(Suppl.1):S2-S19
53. Macoska J. A., Adsule S., Tantivejkul K., Wang S., Pienta K. J., Lee C. T.: - (-) Gossypol promotes the apoptosis of bladder cancer cells in vitro. Pharmacol. Res., 2008;58:323-331
54. L mutations suppress cellular sensitivity to antimycin A. J. Biol. Chem., 2004;279:2159-2165
55. McCoy F., Hurwitz J., McTavish N., Paul I., Barnes C., O'Hagan B., Odrzywol K., Murray J., Longley D., McKerr G., Fennell D. A.: Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Dis., 2010;1:e108
56. Meng Y., Li Y., Li J., Li H., Fu J., Liu Y., Liu H., Chen X.: (-) Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells. Leuk. Lymphoma, 2007;48:2204-2212
57. Miller L. A., Goldstein N. B., Johannes W. U., Walton C. H., Fujita M., Norris D. A., Shellman Y. G.: BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J. Invest. Dermatol., 2009;129:964-971
58. Mitsiades C. S., Hayden P., Kotoula V., McMillin D. W., McMullan C., Negri J., Delmore J. E., Poulaki V., Mitsiades N.: Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. J. Clin. Endocrinol. Metab., 2007;92:4845-4852
59. L [(-)-gossypol] against diffuse large cell lymphoma. Mol. Cancer Ther., 2005;4:13-21
60. Mohan N., Karmakar S., Choudhury S. R., Banik N. L., Ray S. K.: Bcl-2 inhibitor HA14-1 and genistein together adeptly down regulated survival factors and activated cysteine proteases for apoptosis in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells. Brain Res., 2009;1283:155-166
61. Moon D. O., Choi Y. H., Moon S. K., Kim W. J., Kim G. Y.: Gossypol decreases tumor necrosis factor-α-induced intercellular adhesion molecule-1 expression via suppression of NF-κB activity. Food Chem. Toxicol., 2011;49:999-1005
62. Moon D. O., Kim M. O., Kang S. H., Choi Y. H., Park S. Y., Kim G. Y.: HA14-1 sensitizes TNF-α-induced apoptosis via inhibition of the NF-κB signaling pathway: involvement of reactive oxygen species and JNK. Cancer Lett., 2010;292:111-118
63. Mott J. L., Bronk S. F., Mesa R. A., Kaufmann S. H., Gores G. J.: BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol. Cancer Ther., 2008;7:2339-2347
64. Nakamura M., Ishida E., Shimada K., Nakase H., Sakaki T., Konishi N.: Frequent HRK inactivation associated with low apoptotic index in secondary glioblastomas. Acta Neuropathol., 2005;110:402-410
65. Nguyen M., Marcellus R. C., Roulston A., Watson M., Serfass L., Murthy Madiraju S. R., Goulet D., Viallet J., Bélec L., Billot X., Acoca S., Purisima E., Wiegmans A., Cluse L., Johnstone R. W., Beauparlant P., Shore G. C.: Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. USA, 2007;104:19512-19517
66. Oakes S. R., Vaillant F., Lim E., Lee L., Breslin K., Feleppa F., Deb S., Ritchie M. E., Takano E., Ward T., Fox S. B., Generali D., Smyth G. K., Strasser A., Huang D. C., Visvader J. E., Lindeman G. J.: Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc. Natl. Acad. Sci. USA (w druku)
67. O'Brien S. M., Claxton D. F., Crump M., Faderl S., Kipps T., Keating M. J., Viallet J., Cheson B. D.: Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood, 2009;113:299-305
68. Oliver C. L., Miranda M. B., Shangary S., Land S., Wang S., Johnson D. E.: (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2-and Bcl-XL-mediated apoptosis resistance. Mol. Cancer Ther., 2005;4:23-31
69. Oltersdorf T., Elmore S. W., Shoemaker A. R., Armstrong R. C., Augeri D. J., Belli B. A., Bruncko M., Deckwerth T. L., Dinges J., Hajduk P. J., Joseph M. K., Kitada S., Korsmeyer S. J., Kunzer A. R., Letai A., Li C., Mitten M. J., Nettesheim D. G., Ng S., Nimmer P. M., O'Connor J. M., Oleksijew A., Petros A. M., Reed J. C., Shen W., Tahir S. K., Thompson C. B., Tomaselli K. J., Wang B., Wendt M. D., Zhang H., Fesik S. W., Rosenberg S. H.: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005;435:677-681
70. Pan J., Cheng C., Verstovsek S., Chen Q., Jin Y., Cao Q.: The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett., 2010;293:167-174
71. Paoluzzi L., Gonen M., Gardner J. R., Mastrella J., Yang D., Holmlund J., Sorensen M., Leopold L., Manova K., Marcucci G., Heaney M. L., O'Connor O. A.: Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood, 2008;111:5350-5358
72. L inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activivty. Cell Cycle, 2008;7:3211-3224
73. L reveal affinity for Beclin 1 and gossypol. Biochem. Biophys. Res. Commun., 2010;394:515-521
74. Ray S., Bucur O., Almasan A.: Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis, 2005;10:1411-1418
75. Reiners J. J. Jr., Kassel D.: Susceptibility of myelomonocytic leukemia U937 cells to the induction of apoptosis by the non-peptidic Bcl-2 ligand HA14-1 is cell cycle phase-dependent. Cancer Lett., 2005;221:153-163
76. Shamas-Din A., Brahmbhatt H., Leber B., Andrews D. W.: BH3-only proteins: Orchestrators of apoptosis. Biochim. Biophys. Acta, 2011;1813:508-520
77. Shoemaker A. R., Mitten M. J., Adickes J., Ackler S., Refici M., Ferguson D., Oleksijew A., O'Connor J. M., Wang B., Frost D. J., Bauch J., Marsh K., Tahir S. K., Yang X., Tse C., Fesik S. W., Rosenberg S. H., Elmore S. W.: Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin. Cancer Res., 2008;14:3268-3277
78. Skommer J., Wlodkowic D., Mättö M., Eray M., Pelkonen J.: HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk. Res., 2006;30:322-331
79. Smoot R. L., Blechacz B. R., Werneburg N. W., Bronk S. F., Sinicrope F. A., Sirica A. E., Gores G. J.: A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res., 2010;70:1960-1969
80. Swoboda E., Strza̧dała L.: BNIP3 jako nietypowy przedstawiciel rodziny Bcl-2. Czȩść 1: BNIP3 - regulator nieapoptycznej programowanej śmierci komórek. Postȩpy Hig. Med. Dośw., 2009;63:409-417
81. Tahir S. K., Yang X., Anderson M. G., Morgan-Lappe S. E., Sarthy A. V., Chen J., Warner R. B., Ng S. C., Fesik S. W., Elmore S. W., Rosenberg S. H., Tse C.: Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res., 2007;67:1176-1183
82. Tian D., Das S. G., Doshi J. M., Peng J., Lin J., Xing C.: sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell. Cancer Lett., 2008;259:198-208
83. Trudel S., Li Z. H., Rauw J., Tiedemann R. E., Wen X. Y., Stewart A. K.: Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood, 2007;109:5430-5438
84. Tse C., Shoemaker A. R., Adickes J., Anderson M. G., Chen J., Jin S., Johnson E. F., Marsh K. C., Mitten M. J., Nimmer P., Roberts L., Tahir S. K., Xiao Y., Yang X., Zhang H., Fesik S., Rosenberg S. H., Elmore S. W.: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res., 2008;68:3421-3428
85. Tuszynski G. P., Cossu G.: Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res., 1984;44:768-771
86. van Delft M. F., Wei A. H., Mason K. D., Vandenberg C. J., Chen L., Czabotar P. E., Willis S. N., Scott C. L., Day C. L., Cory S., Adams J. M., Roberts A. W., Huang D. C.: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006;10:389-399
87. Verhaegen M., Bauer J. A., Martin de la Vega C., Wang G., Wolter K. G., Brenner J. C., Nikolovska-Coleska Z., Bengtson A., Nair R., Elder J. T., Van Brocklin M., Carey T. E., Bradford C. R., Wang S., Soengas M. S.: A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res., 2006;66:11348-11359
88. L and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood, 2009;113:4403-4413
89. Vogler M., Dickens D., Dyer M. J., Owen A., Pirmohamed M., Cohen G. M.: The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem. Biophys. Res. Commun., 2011;408:344-349
90. Vogler M., Furdas S. D., Jung M., Kuwana T., Dyer M. J., Cohen G. M.: Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin. Cancer Res., 2010;16:4217-4225
91. Walensky L. D., Kung A. L., Escher I., Malia T. J., Barbuto S., Wright R. D., Wagner G., Verdine G. L., Korsmeyer S. J.: Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science, 2004;305:1466-1470
92. Wang L., Kong F., Kokoski C. L., Andrews D. W., Xing C.: Development of dimeric modulators for anti-apoptotic Bcl-2 proteins. Bioorg. Med. Chem. Lett., 2008;18:236-240
93. Wang Z., Azmi A. S., Ahmad A., Banerjee S., Wang S., Sarkar F. H., Mohammad R. M.: TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res., 2009;69:2757-2765
94. Weber A., Kirejczyk Z., Potthoff S., Ploner C., Häcker G.: Endogenous Noxa determines the strong proapoptotic synergism of the BH3-mimetic ABT-737 with chemotherapeutic agents in human melanoma cells. Transl. Oncol., 2009;2:73-83
95. L, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev., 2005;19:1294-1305
96. L family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin. Cancer Res., 2007;13:7191-7198
97. Yang B., Liu D., Huang Z.: Synthesis and helical structure of lactam bridged BH3 peptides derived from pro-apoptotic Bcl-2 family proteins. Bioorg. Med. Chem. Lett., 2004;14:1403-1406
98. Yecies D., Carlson N. E., Deng J., Letai A.: Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood, 2010;115:3304-3313
99. L and induction of autophagy. EMBO Rep., 2009;10:285-292
100. Zheng L., Yang W., Zhang C., Ding W. J., Zhu H., Lin N. M., Wu H. H., He Q. J., Yang B.: GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett., 2011;309:27-36